CCND1 and nonpapillary renal cell carcinoma: Recently, novel sequencing technologies have provided impetus to further investigate the potential of circulating mRNA and consequently CDK18 and CCND1 messengers were shown to be downregulated in blood of ccRCC patients (65) (Table 2).